by Elena Iemma | Jun 23, 2026 | News
EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded...
by Elena Iemma | May 19, 2025 | Blog
FDA Roadmap to Reducing Animal Testing:A Step Toward Smarter Tools for in silico Immunogenicity Risk Assessment The FDA’s new Roadmap to Reducing Animal Testing in Preclinical Safety Studies lays out a phased plan to move away from animal models and toward...
